|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Heidenreich A and Pfister D: Treatment
decisions for metastatic castration-resistant prostate cancer
progressing after docetaxel chemotherapy: the role of cabazitaxel
in the continuum of care. Eur Urol. 62:1201–1204. 2012. View Article : Google Scholar
|
|
3
|
Beltran H, Beer TM, Carducci MA, et al:
New therapies for castration-resistant prostate cancer: efficacy
and safety. Eur Urol. 60:279–290. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mottet N, Bellmunt J, Bolla M, et al: EAU
guidelines on prostate cancer. Part II: Treatment of advanced,
relapsing, and castration-resistant prostate cancer. Eur Urol.
59:572–583. 2011. View Article : Google Scholar
|
|
5
|
Vitale DC, Piazza C, Melilli B, Drago F
and Salomone S: Isoflavones: estrogenic activity, biological effect
and bioavailability. Eur J Drug Metab Pharmacokinet. 38:15–25.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ko CH, Shen SC, Lin HY, et al: Flavanones
structure-related inhibition on TPA-induced tumor promotion through
suppression of extracellular signal-regulated protein kinases:
involvement of prostaglandin E2 in anti-promotive process. J Cell
Physiol. 193:93–102. 2002. View Article : Google Scholar
|
|
7
|
Romagnolo DF and Selmin OI: Flavonoids and
cancer prevention: a review of the evidence. J Nutr Gerontol
Geriatr. 31:206–238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Manthey JA, Grohmann K and Guthrie N:
Biological properties of citrus flavonoids pertaining to cancer and
inflammation. Curr Med Chem. 8:135–153. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsiao YC, Kuo WH, Chen PN, et al:
Flavanone and 2′-OH flavanone inhibit metastasis of lung cancer
cells via down-regulation of proteinases activities and MAPK
pathway. Chem Biol Interact. 167:193–206. 2007.
|
|
10
|
Nagaprashantha LD, Vatsyayan R, Singhal J,
et al: 2′-hydroxyflavanone inhibits proliferation, tumor
vascularization and promotes normal differentiation in VHL-mutant
renal cell carcinoma. Carcinogenesis. 32:568–575. 2011.
|
|
11
|
Shin SY, Kim JH, Lee JH, Lim Y and Lee YH:
2′-Hydroxyflavanone induces apoptosis through Egr-1 involving
expression of Bax, p21, and NAG-1 in colon cancer cells. Mol Nutr
Food Res. 56:761–774. 2012.
|
|
12
|
Wu K, Gore C, Yang L, et al: Slug, a
unique androgen-regulated transcription factor, coordinates
androgen receptor to facilitate castration resistance in prostate
cancer. Mol Endocrinol. 26:1496–1507. 2012. View Article : Google Scholar
|
|
13
|
Turkson J, Bowman T, Garcia R, Caldenhoven
E, De Groot RP and Jove R: Stat3 activation by Src induces specific
gene regulation and is required for cell transformation. Mol Cell
Biol. 18:2545–2552. 1998.PubMed/NCBI
|
|
14
|
Wu K, Fan J, Zhang L, et al: PI3K/Akt to
GSK3β/β-catenin signaling cascade coordinates cell colonization for
bladder cancer bone metastasis through regulating ZEB1
transcription. Cell Signal. 24:2273–2282. 2012.
|
|
15
|
Youle RJ and Strasser A: The BCL-2 protein
family: opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Majumder PK and Sellers WR: Akt-regulated
pathways in prostate cancer. Oncogene. 24:7465–7474. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nelson EC, Evans CP, Mack PC, Devere-White
RW and Lara PN Jr: Inhibition of Akt pathways in the treatment of
prostate cancer. Prostate Cancer Prostatic Dis. 10:331–339. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morgan TM, Koreckij TD and Corey E:
Targeted therapy for advanced prostate cancer: inhibition of the
PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 9:237–249. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mora LB, Buettner R, Seigne J, et al:
Constitutive activation of Stat3 in human prostate tumors and cell
lines: direct inhibition of Stat3 signaling induces apoptosis of
prostate cancer cells. Cancer Res. 62:6659–6666. 2002.PubMed/NCBI
|
|
20
|
Gaya JM, Ahallal Y, Sanchez-Salas R, et
al: Current, new and novel therapy for castration-resistant
prostate cancer. Expert Rev Anticancer Ther. 13:819–827. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu KJ, Zeng J, Zhu GD, et al: Silibinin
inhibits prostate cancer invasion, motility and migration by
suppressing vimentin and MMP-2 expression. Acta Pharmacol Sin.
30:1162–1168. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu K, Zeng J, Li L, et al: Silibinin
reverses epithelial-to-mesenchymal transition in metastatic
prostate cancer cells by targeting transcription factors. Oncol
Rep. 23:1545–1552. 2010.PubMed/NCBI
|
|
23
|
Zeng J, Sun Y, Wu K, et al:
Chemopreventive and chemotherapeutic effects of intravesical
silibinin against bladder cancer by acting on mitochondria. Mol
Cancer Ther. 10:104–116. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu K, Ning Z, Zeng J, et al: Silibinin
inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer
metastasis via dual-blocking epithelial-mesenchymal transition and
stemness. Cell Signal. 25:2625–2633. 2013.
|
|
25
|
Stanbrough M, Bubley GJ, Ross K, et al:
Increased expression of genes converting adrenal androgens to
testosterone in androgen-independent prostate cancer. Cancer Res.
66:2815–2825. 2006. View Article : Google Scholar
|
|
26
|
Yuan X, Cai C, Chen S, Yu Z and Balk SP:
Androgen receptor functions in castration-resistant prostate cancer
and mechanisms of resistance to new agents targeting the androgen
axis. Oncogene. Jun 10–2013.(Epub ahead of print). View Article : Google Scholar
|
|
27
|
Adeniji AO, Chen M and Penning TM: AKR1C3
as a target in castrate resistant prostate cancer. J Steroid
Biochem Mol Biol. 37:136–149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ofude M, Mizokami A, Kumaki M, et al:
Repression of cell proliferation and androgen receptor activity in
prostate cancer cells by 2′-hydroxyflavanone. Anticancer Res.
33:4453–4461. 2013.
|
|
29
|
Zielinski RR, Eigl BJ and Chi KN:
Targeting the apoptosis pathway in prostate cancer. Cancer J.
19:79–89. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Real PJ, Sierra A, De Juan A, Segovia JC,
Lopez-Vega JM and Fernandez-Luna JL: Resistance to chemotherapy via
Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer
cells. Oncogene. 21:7611–7618. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang D, He D, Xue Y, et al: PrLZ protects
prostate cancer cells from apoptosis induced by androgen
deprivation via the activation of Stat3/Bcl-2 pathway. Cancer Res.
71:2193–2202. 2011. View Article : Google Scholar : PubMed/NCBI
|
